Work

90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.03.105

Authors: G. Rossi, E. Brain, A. Dueck, H. De Swert, S.I. Marreaud, A. Partridge, C. Herold, H. Vachon, T. Spanic, A. Arahmani, T. Verbiest, L. Wang, T. Goulioti, B. Malanda, L.A. Carey, S. Anneheim, G. Paux, C. Poncet, O. Metzger, D. Cameron

Institutions: Breast International Group, Hôpital René Huguenin, Institut Curie, Alliance Foundation Trials, European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer, Europa Donna, Sanofi (United States), UNC Lineberger Comprehensive Cancer Center, Sanofi (France), Western General Hospital, Edinburgh Cancer Research, Institute of Genetics and Cancer

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4229028011

FWCI: 0.161

Cites:

Cited by: 1

Related to: 10